AR057188A1 - 3-amino-2-arilpropil azaindoles y usos de los mismos - Google Patents

3-amino-2-arilpropil azaindoles y usos de los mismos

Info

Publication number
AR057188A1
AR057188A1 ARP060105231A ARP060105231A AR057188A1 AR 057188 A1 AR057188 A1 AR 057188A1 AR P060105231 A ARP060105231 A AR P060105231A AR P060105231 A ARP060105231 A AR P060105231A AR 057188 A1 AR057188 A1 AR 057188A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
pyrrolopyridin
pyrrolopyrimidin
oxide
Prior art date
Application number
ARP060105231A
Other languages
English (en)
Inventor
Robert Greenhouse
Saul Jaime Figueroa
Stephen M Lynch
Lubica Raptova
Karin Ann Stein
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057188A1 publication Critical patent/AR057188A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

También se aportan composiciones farmacéuticas, métodos de utilizacion y métodos de preparacion de los compuestos. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable de los mismos, en la que p es 1 o 2; Ar es: pirrolopiridinilo seleccionado del grupo formado por pirrolopiridin-1-ilo, pirrolopiridin-2-ilo y pirrolopiridin-3-ilo, cada uno de los cuales puede ser opcionalmente sustituido; N-oxido de pirrolopiridinilo seleccionado del grupo formado por N- oxido de pirrolopiridin-1-ilo, N-oxido de pirrolopiridin-12ilo y N-oxido de pirrolopiridin-3-ilo, cada uno de los cuales puede ser opcionalmente sustituido; o pirrolopirimidinilo seleccionado del grupo formado por: pirrolopirimidin-5-ilo, pirrolopirimidin-6-ilo y pirrolopirimidin-7-ilo, cada uno de los cuales puede ser opcionalmente sustituido; R1 es: (a) arilo seleccionado de entre fenilo y naftilo, cada uno opcionalmente sustituido; o (b) heteroarilo seleccionado de entre indolilo, piridinilo, tienilo, furanilo, pirimidinilo, piridazinilo, pirazinilo, oxazolilo, tiazolilo, isoxazolilo, isotiazolilo, imidazolilo, pirazolilo, quinolinilo e isoquinolinilo, cada uno opcionalmente sustituido; (c) arilalquilo opcionalmente sustituido; (d) heteroarilalquilo opcionalmente sustituido; (e) cicloalquilo; (f) cicloalquilmetilo; o (g) alquilo ramificado; R2 es: (a) H; (b) alquilo; (c) hidroxialquilo; (d) alcoxialquilo; fluoro; o alquilo; Rb es H, alquilo, hidroxi, alcoxi, fluoro, o hidroxialquilo; o uno de R2 y R3 junto con uno de Ra y Rb y los átomos a los que están unidos pueden constituir un anillo de 5 o 6 miembros que opcionalmente incluye un heteroátomo adicional seleccionado de entre O, N y S; Rc y Rd son cada uno de forma independiente: H o alquilo; o Rc y Rd juntos forman =O, =S, o =NRf, en el que Rf es H, alquilo, o -ORg, en el que Rg es H o alquilo; o uno de R2 y R3 junto con uno de Rc y Rd junto con los átomos a los que están unidos pueden constituir un anillo de 4 a 6 miembros que de forma opcional incluye un heteroátomo adicional seleccionado de entre O, N y s; y Re es H o alquilo.
ARP060105231A 2005-11-30 2006-11-28 3-amino-2-arilpropil azaindoles y usos de los mismos AR057188A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74127205P 2005-11-30 2005-11-30

Publications (1)

Publication Number Publication Date
AR057188A1 true AR057188A1 (es) 2007-11-21

Family

ID=37667384

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105231A AR057188A1 (es) 2005-11-30 2006-11-28 3-amino-2-arilpropil azaindoles y usos de los mismos

Country Status (17)

Country Link
US (2) US7638517B2 (es)
EP (1) EP1957488B1 (es)
JP (1) JP2009517432A (es)
KR (1) KR101026570B1 (es)
CN (1) CN101321752A (es)
AR (1) AR057188A1 (es)
AT (1) ATE442368T1 (es)
AU (1) AU2006319233B9 (es)
BR (1) BRPI0619184A2 (es)
CA (1) CA2632284A1 (es)
DE (1) DE602006009138D1 (es)
ES (1) ES2329413T3 (es)
NO (1) NO20082112L (es)
RU (1) RU2008120141A (es)
TW (1) TW200804376A (es)
WO (1) WO2007062998A1 (es)
ZA (1) ZA200804299B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
US7871802B2 (en) * 2007-10-31 2011-01-18 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
CN102026988B (zh) * 2008-06-05 2013-07-03 爱思开生物制药株式会社 3-取代的丙胺化合物
US8101642B2 (en) * 2008-06-05 2012-01-24 Sk Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011143646A1 (en) * 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
AR098436A1 (es) * 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
CN108034283B (zh) * 2017-12-15 2020-10-13 淮海工学院 一种聚乙二醇化苯并吲哚七甲川菁染料及其制备方法和应用
WO2020160174A1 (en) * 2019-01-29 2020-08-06 Universita Degli Studi Di Padova Uses of compounds having anti-hsv-1 activity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE849108C (de) 1948-10-01 1952-09-11 Hoechst Ag Verfahren zur Herstellung von 1-disubstituierten 3-Aminopropanen
GB705652A (en) 1948-10-01 1954-03-17 Farbewerke Hoechst Ag Manufacture of 3-aminopropane compounds
NL82464C (es) 1952-01-05
US2708197A (en) 1952-05-24 1955-05-10 Upjohn Co Preparation of (hydroxy-3-indole)-alkylamines
US2984670A (en) 1959-05-22 1961-05-16 Upjohn Co Novel 3-(1-hydroxy-1-phenyl-3-aminopropyl) indoles
GB992731A (en) 1962-09-28 1965-05-19 Koninklijke Pharma Fab Nv Aminoalkyl-indolyl-benzyl alcohols
US4616080A (en) 1984-07-02 1986-10-07 Eli Lilly And Company Simplified process of forming crystalline ceftazidime pentahydrate
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
JP2779240B2 (ja) * 1987-12-11 1998-07-23 三井化学株式会社 新規アミン類およびその用途
JPH0314562A (ja) 1988-04-11 1991-01-23 Nippon Chemiphar Co Ltd 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
US5177088A (en) 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
US5185350A (en) 1991-09-23 1993-02-09 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles
EP0600830A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Substituierte Derivate von Diaminophthalimid als Protein-Tyrosin-Kinase-Hemmer
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
GB9523948D0 (en) 1995-11-23 1996-01-24 Univ East Anglia Process for preparing n-benzyl indoles
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
CA2256492C (en) 1996-05-20 2006-04-04 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
EP0912494A1 (en) 1996-06-07 1999-05-06 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0887348A1 (en) 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1027046A4 (en) 1997-10-28 2002-04-03 Merck & Co Inc GONADOTROPIN RELEASING HORMON ANTAGONISTS
JP2001520997A (ja) 1997-10-28 2001-11-06 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
FR2780890B3 (fr) 1998-07-10 2000-09-01 Sanofi Sa Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour le traitement des glomerulonephrites chroniques
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
FR2814073B1 (fr) 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
GB0112122D0 (en) * 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
EP1448557A4 (en) 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2002360819A1 (en) 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
US7244847B2 (en) 2002-02-06 2007-07-17 Isis Pharmaceuticals, Inc. Benzimidazole compounds
EP1496838B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
US7667053B2 (en) * 2002-04-12 2010-02-23 Merck & Co., Inc. Bicyclic amides
MXPA05011841A (es) * 2003-05-09 2006-01-26 Hoffmann La Roche Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1.
WO2005005439A1 (en) 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
EP1663113A4 (en) * 2003-09-18 2007-06-13 Merck & Co Inc SUBSTITUTED SULFONAMIDES
CN1871208A (zh) * 2003-10-30 2006-11-29 默克公司 作为大麻素受体调节剂的芳烷基胺
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
NZ551292A (en) * 2004-06-01 2009-11-27 Hoffmann La Roche 3-Amino-1-arylpropyl indoles as monoamine reuptake inhibitor
JP2009510066A (ja) * 2005-09-29 2009-03-12 ワイス 血管運動症状（ｖｍｓ）の治療のためのモノアミン再取り込みのモジュレータである１−（１ｈ−インドール−１−イル）−３−（メチルアミノ）−１−フェニルプロパン−２−オール誘導体および関連の化合物

Also Published As

Publication number Publication date
DE602006009138D1 (de) 2009-10-22
ATE442368T1 (de) 2009-09-15
BRPI0619184A2 (pt) 2011-09-13
KR101026570B1 (ko) 2011-03-31
TW200804376A (en) 2008-01-16
KR20080064192A (ko) 2008-07-08
RU2008120141A (ru) 2010-01-10
AU2006319233B2 (en) 2011-06-02
US7638517B2 (en) 2009-12-29
CN101321752A (zh) 2008-12-10
CA2632284A1 (en) 2007-06-07
ES2329413T3 (es) 2009-11-25
ZA200804299B (en) 2009-04-29
EP1957488B1 (en) 2009-09-09
AU2006319233A1 (en) 2007-06-07
WO2007062998A1 (en) 2007-06-07
US20070123535A1 (en) 2007-05-31
JP2009517432A (ja) 2009-04-30
EP1957488A1 (en) 2008-08-20
NO20082112L (no) 2008-06-23
US20100056499A1 (en) 2010-03-04
AU2006319233B9 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
AR057188A1 (es) 3-amino-2-arilpropil azaindoles y usos de los mismos
PE20220143A1 (es) Agonistas de glp-1r y usos de los mismos
JP6073677B2 (ja) 縮合複素環式化合物およびそれらの使用
BR112019012957A2 (pt) derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
AR080754A1 (es) Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AR078841A1 (es) Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10
ES2292130T3 (es) Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos.
ES2320955B1 (es) Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
HRP20230595T1 (hr) Inhibitori lizina specifične demetilaze-1
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
HRP20190604T1 (hr) Supstituirani spojevi dihidroizokinolinona
ES2661510T3 (es) Uso de inhibidores de la actividad o función de PI3K
PE20190653A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
JP2010506850A5 (es)
AR060537A1 (es) 1,2,4-triazoles trisustituidos
AR044940A1 (es) Compuestos heterociclicos y su uso como moduladores de gamma opioides
AR092684A1 (es) Compuestos de sulfonamida sustituidos
JP2016512834A5 (es)
HRP20212021T1 (hr) 4-IMIDAZOPIRIDAZIN-1-iL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI KAO INHIBITORI BTK
JP2008525498A5 (es)
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
KR20130006664A (ko) 인다졸 화합물 및 그의 용도
AR119018A1 (es) Inhibidores de proteína quinasas dependientes de adn
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure